Literature DB >> 19780644

Outcomes following single-treatment Gamma Knife surgery for trigeminal neuralgia with a minimum 3-year follow-up.

Ron I Riesenburger1, Steven W Hwang, Clemens M Schirmer, Vasilios Zerris, Julian K Wu, Kerry Mahn, Paul Klimo, John Mignano, Clinton J Thompson, Kevin C Yao.   

Abstract

OBJECT: Gamma Knife surgery (GKS) has been shown to be effective in treating trigeminal neuralgia (TN). Existing studies have demonstrated success rates of 69.1-85% with median follow-up intervals of 19-60 months. However, series with uniform long-term follow-up data for all patients have been lacking. In the present study the authors examined outcomes in a series of patients with TN who underwent a single GKS treatment followed by a minimum follow-up of 36 months. They used a clinical scale that simplifies the reporting of outcome data for patients with TN.
METHODS: Fifty-three consecutive patients with typical, intractable TN received a median maximum radiation dose of 80 Gy applied with a single 4-mm isocenter to the affected trigeminal nerve. Follow-up data were obtained by clinical examination and questionnaire. Outcome results were categorized into the following classes (in order of decreasing success): Class 1A, complete pain relief without medications; 1B, complete pain relief with either a decrease or no change in medications; 1C, > or = 50% pain relief without medications; 1D, > or = 50% pain relief with either a decrease or no change in medications; and Class 2, < 50% pain relief and/or increase in medications. Patients with Class 1A-1D outcome (equivalent to Barrow Neurological Institute Grades I-IIIb) were considered to have a good treatment outcome, whereas in patients with Class 2 outcome (equivalent to Barrow Neurological Institute Grades IV and V) treatment was considered to have failed.
RESULTS: A good treatment outcome from initial GKS was achieved in 31 (58.5%) patients for whom the mean follow-up period was 48 months (range 36-66 months). Outcomes at last follow-up were reflected by class status: Class 1A, 32.1% of patients; 1B, 1.9%; 1C, 3.8%; 1D, 20.8%; and Class 2, 41.5%. Statistical analysis showed no difference in outcomes between patients previously treated with microvascular decompression or rhizotomy compared with patients with no previous surgical treatments. Thirty-six percent of patients reported some degree of posttreatment facial numbness. Anesthesia dolorosa did not develop in any patient.
CONCLUSIONS: Despite a time-dependent deterioration in the success rate of GKS for medically intractable TN, the authors' study showed that > 50% of patients can be expected to have a good outcome based on their scoring system, with approximately 33% having an ideal outcome (pain free with no need for medications). Long-term data, as those presented here, are important when counseling patients on their treatment options.

Entities:  

Mesh:

Year:  2010        PMID: 19780644     DOI: 10.3171/2009.8.JNS081706

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Current gamma knife treatment for ophthalmic branch of primary trigeminal neuralgia.

Authors:  Guo-Yong Shan; Hao-Fang Liang; Jian-Hua Zhang
Journal:  Int J Ophthalmol       Date:  2011-04-18       Impact factor: 1.779

2.  Stereotactic radiosurgery of essential trigeminal neuralgia using Leksell Gamma Knife model C with automatic positioning system: technical nuances and evaluation of outcome in 130 patients with at least 2 years follow-up after treatment.

Authors:  Motohiro Hayashi; Mikhail Chernov; Noriko Tamura; Takaomi Taira; Masahiro Izawa; Shoji Yomo; Mariko Nagai; Cheng-Siu Chang; Pavel Ivanov; Manabu Tamura; Yoshihiro Muragaki; Yoshikazu Okada; Hiroshi Iseki; Kintomo Takakura
Journal:  Neurosurg Rev       Date:  2011-06-24       Impact factor: 3.042

3.  Predictive nomogram for the durability of pain relief from gamma knife radiation surgery in the treatment of trigeminal neuralgia.

Authors:  John T Lucas; Adrian M Nida; Scott Isom; Kopriva Marshall; John D Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-07       Impact factor: 7.038

Review 4.  Surgical management of medically refractory trigeminal neuralgia.

Authors:  Bruce E Pollock
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

5.  Trigeminal nerve integrated dose and pain outcome after gamma knife radiosurgery for trigeminal neuralgia.

Authors:  Hussein Alahmadi; Gelareh Zadeh; Norman Laperriere; Shobhan Vachhrajani; Nura Mazloom; Fred Gentili; Mojgan Hodaie
Journal:  J Radiosurg SBRT       Date:  2012

6.  Clinical outcomes of gamma knife radiosurgery in the treatment of patients with trigeminal neuralgia.

Authors:  Ameer L Elaimy; Peter W Hanson; Wayne T Lamoreaux; Alexander R Mackay; John J Demakas; Robert K Fairbanks; Barton S Cooke; Sudheer R Thumma; Christopher M Lee
Journal:  Int J Otolaryngol       Date:  2011-10-25

7.  Trigeminal neuralgia treatment outcomes following Gamma Knife radiosurgery with a minimum 3-year follow-up.

Authors:  Sana D Karam; Alexander Tai; Margaux Wooster; Abdul Rashid; Rosanna Chen; Nimrah Baig; Ann Jay; K William Harter; Pamela Randolph-Jackson; Adedamola Omogbehin; Edward F Aulisi; Jeff Jacobson
Journal:  J Radiat Oncol       Date:  2013-11-20

8.  Salvage Gamma Knife Radiosurgery after failed management of bilateral trigeminal neuralgia.

Authors:  Ami B Raval; Jennifer Salluzzo; Tomas Dvorak; Lori Lyn Price; John E Mignano; Julian K Wu
Journal:  Surg Neurol Int       Date:  2014-11-21

Review 9.  Advances in diagnosis and treatment of trigeminal neuralgia.

Authors:  Nicola Montano; Giulio Conforti; Rina Di Bonaventura; Mario Meglio; Eduardo Fernandez; Fabio Papacci
Journal:  Ther Clin Risk Manag       Date:  2015-02-24       Impact factor: 2.423

10.  Long term outcomes of gamma knife radiosurgery for typical trigeminal neuralgia-minimum 5-year follow-up.

Authors:  Jong Kwon Lee; Hyuk Jai Choi; Hak Cheol Ko; Seok Keun Choi; Young Jin Lim
Journal:  J Korean Neurosurg Soc       Date:  2012-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.